Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (161-170 of 264) with videos related to

Pageof 27
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 17, 2007
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study GroupLorenzo Gianni, Bernard F Cole, Ilaria Panzini, et al.
The Oncologist|March 7, 2009
Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 yearsAliana Guerrieri-Gonzaga, Edoardo Botteri, Nicole Rotmensz, et al.
Plos Genetics|January 3, 2023
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT TrialsMeredith M Regan, Prudence A Francis, Olivia Pagani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenMitch Dowsett, Jack Cuzick, Jim Ingle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFTOlivia Pagani, Prudence A Francis, Gini F Fleming, et al.
Breast Cancer Research and Treatment|July 4, 2016
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00Giancarlo Pruneri, Kathryn P Gray, Andrea Vingiani, et al.
Breast Cancer Research and Treatment|March 29, 2018
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00Elisabetta Munzone, Kathryn P Gray, Caterina Fumagalli, et al.
Critical Reviews in Oncology/Hematology|July 23, 2013
Breast phyllodes tumor: a review of literature and a single center retrospective series analysisGianluca Spitaleri, Antonio Toesca, Edoardo Botteri, et al.
Breast Cancer Research and Treatment|November 7, 2020
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trialManuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, et al.
Pageof 27

Showing results (161-170 of 264) with videos related to

Sort By:
Pageof 27
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 17, 2007
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study GroupLorenzo Gianni, Bernard F Cole, Ilaria Panzini, et al.
The Oncologist|March 7, 2009
Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 yearsAliana Guerrieri-Gonzaga, Edoardo Botteri, Nicole Rotmensz, et al.
Plos Genetics|January 3, 2023
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT TrialsMeredith M Regan, Prudence A Francis, Olivia Pagani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenMitch Dowsett, Jack Cuzick, Jim Ingle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFTOlivia Pagani, Prudence A Francis, Gini F Fleming, et al.
Breast Cancer Research and Treatment|July 4, 2016
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00Giancarlo Pruneri, Kathryn P Gray, Andrea Vingiani, et al.
Breast Cancer Research and Treatment|March 29, 2018
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00Elisabetta Munzone, Kathryn P Gray, Caterina Fumagalli, et al.
Critical Reviews in Oncology/Hematology|July 23, 2013
Breast phyllodes tumor: a review of literature and a single center retrospective series analysisGianluca Spitaleri, Antonio Toesca, Edoardo Botteri, et al.
Breast Cancer Research and Treatment|November 7, 2020
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trialManuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, et al.
Pageof 27